The tech giant and the non-profit research org hope to leverage artificial intelligence to prevent disease and accelerate biomedical research efforts.
The use of AI in healthcare is currently limited to medical imaging, Scripps’ founder & director Dr. Eric Topol noted in a call with reporters last week. Topol said he expects that deep learning techniques could be used to analyze entire genomic sequences and data from continuous medical sensors, generating insights into disease prevention.
The Nvidia-Scripps team will first focus on creating tools to help predict atrial fibrillation, with an eye on exploring other diseases and datasets down the road – including blood pressure monitoring and blood glucose.
“AI has tremendous promise to transform the future of medicine,” Topol said in prepared remarks. “With Nvidia, we aim to establish a center of excellence for artificial intelligence in genomics and digital sensors, with the ultimate goal of developing best practices, tools and AI infrastructure for broader adoption and application by the biomedical research community.”
“AI is already transforming healthcare by using electronic health records and medical imaging to better diagnose and treat disease,” Kimberly Powell, VP of healthcare at Nvidia, added. “Our collaboration with Scripps expands these opportunities by tapping into the rapid accessibility of genomic and digital wearable data, and furthers the quest to better predict and prevent disease.”